KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Long-Term Debt Repayments (2019 - 2023)

Aquestive Therapeutics (AQST) has 3 years of Long-Term Debt Repayments data on record, last reported at $9.1 million in Q1 2023.

  • For Q1 2023, Long-Term Debt Repayments changed N/A year-over-year to $9.1 million; the TTM value through Mar 2023 reached $31.6 million, up 40.38%, while the annual FY2025 figure was $26000.0, 13.04% up from the prior year.
  • Long-Term Debt Repayments reached $9.1 million in Q1 2023 per AQST's latest filing, down from $22.5 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $49.4 million in Q3 2019 and bottomed at $9.1 million in Q1 2023.
  • Average Long-Term Debt Repayments over 3 years is $27.0 million, with a median of $22.5 million recorded in 2020.